newsfilter
← Latest News
Business Wire·

Precision BioSciences Reports Third Quarter 2025 Financial Results and Provides Business Update

- Late-breaking oral presentation at the Liver Meeting® 2025 to feature new data from multiple cohorts of the Phase 1 ELIMINATE-B trial of PBGENE-HBV in chronic hepatitis B - Commenced dosing in Cohort 3 of the